Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Multicentric reticulohistiocytosis


See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Overview



What is multicentric reticulohistiocytosis?

What are the symptoms of multicentric reticulohistiocytosis?

How might multicentric reticulohistiocytosis be treated?

What is the prognosis for individuals with multicentric reticulohistiocytosis?


What is multicentric reticulohistiocytosis?

Multicentric reticulohistiocytosis is a disease that is characterized by the presence of papules and nodules and associated with arthritis mutilans.[1] The disease can involve the skin, the bones, the tendons, the muscles, the joints, and nearly any other organ (e.g., eyes, larynx, thyroid, salivary glands, bone marrow, heart, lung, kidney, liver, gastrointestinal tract). In the majority of cases, the cause of multicentric reticulohistiocytosis is unknown; however, it has been associated with an underlying cancer in about one fourth of cases, suggesting that it may be a paraneoplastic syndrome.[2][3]
Last updated: 9/28/2012

What are the symptoms of multicentric reticulohistiocytosis?

The main symptoms of multicentric reticulohistiocytosis are arthritis and red to purple skin nodules varying in size from 1 to 10 mm. The nodules can be found on any part of the body but tend to concentrate on the face and hands and decrease in number from head to toe.[2][4] The arthritis is most often symmetrical and polyarticular (affecting many joints). Unlike adult rheumatoid arthritis, it does not spare the joints closest to the fingertips. It can be severely destructive, and in one third of cases it progresses to arthritis multilans. Further history reveals that approximately one third of patients complain of symptoms such as fever, weight loss, and malaise; less often, pericarditis and myositis are present.[2][4]

The clinical presentation of multicentric reticulohistiocytosis is insidious in onset and begins with arthritic complaints in approximately two thirds of patients.  It is potentially one of the most rapidly destructive forms of arthritis. Joint involvement remits and relapses, gradually worsening into a debilitating and permanent arthritis multilans.  The severity of the damage has been reported to be related to the age of onset; therefore, the earlier one has symptoms, the more severe the symptoms tend to be.  Like the associated arthritis, skin lesions tend to wax and wane until the disease spontaneously resolves, but may leave permanent disfigurement.[4]

Last updated: 6/21/2013

How might multicentric reticulohistiocytosis be treated?

Dermatologists and rheumatologists are often the types of specialists that oversee the treatment of patients with multicentric reticulohistiocytosis. Although no specific therapy has consistently been shown to improve multicentric reticulohistiocytosis, many different drugs have been used.[3] For instance, therapy with non-steroidal anti-inflammatory agents (e.g., aspirin or ibuprofen) may help the arthritis. Systemic corticosteroids and/or cytotoxic agents, particularly cyclophosphamide, chlorambucil, or methotrexate, may affect the inflammatory response, prevent further joint destruction, and cause skin lesions to regress. Antimalarials (e.g., hydroxychloroquine and mefloquine) have also been used. Alendronate and other bisphosphonates have been reported to be effective in at least one patient and etanercept and infliximab have been effective in some.[5]
Last updated: 6/21/2013

What is the prognosis for individuals with multicentric reticulohistiocytosis?

After an average course of 8 years, patients often go into remission (a state where symptoms have subsided). The disease can cause considerable morbidity (disability as a result of the disease), mainly related to the occurrence of severe arthritis. The arthritis can come and go, but it can be very severe in about 45% of cases.[3] If the patient has an associated cancer, the prognosis relates to that of the specific cancer.[5]
Last updated: 6/21/2013

References
  1. Chakravarty EF, Genovese MC. Chapter 111 -- Musculoskeletal Syndromes in Malignancy. Harris: Kelley’s Textbook of Rheumatology, 7th ed.. Philadelphia, PA: W.B. Saunders Company; 2005;
  2. West SG. Chapter 297 -- Systemic Diseases in Which Arthritis is a Feature. Goldman: Cecil Textbook of Medicine, 23rd ed.. Philadelphia, PA: Saunders Elsevier; 2008;
  3. Rapini RP, Morgan LT. Dermatologic Manifestations of Multicentric Reticulohistiocytosis . Medscape Reference . June 6, 2012; http://emedicine.medscape.com/article/1058248-overview. Accessed 9/28/2012.
  4. Hsiung et al.. Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis. Journal of the American Academy of Dermatology. 2003;
  5. Callen JP. Multicentric Reticulohistiocytosis. Medscape Reference. August 16, 2011; http://emedicine.medscape.com/article/283885-overview. Accessed 9/28/2012.